
FibroGen (FGEN) Stock Forecast & Price Target
FibroGen (FGEN) Analyst Ratings
Bulls say
FibroGen Inc. is positioned favorably in the biotechnology sector, with promising potential for product candidates such as FG-3246 that may outperform existing standard of care therapies in clinical trials. The company's financial structure is enhanced by the revenue stream from roxadustat, which mitigates reliance on dilutive capital raises, and is further supported by a solid cash reserve of $51 million, not including an anticipated $75 million from the pending sale of FibroGen China to AstraZeneca. This financial stability, along with the strategic regaining of development rights for key therapeutics, underscores a strong outlook for FibroGen as it navigates macroeconomic challenges while advancing its research and development initiatives.
Bears say
FibroGen Inc faces significant risks that could adversely impact its financial outlook, primarily due to the potential for failed or inconclusive clinical trials which would hinder its product development. Additionally, the company may struggle to secure adequate funding necessary to advance its therapeutics, raising concerns about possible dilutive capital raises that could weaken shareholder value. The lack of commercial success and the associated delisting risk further compound these challenges, creating a pessimistic scenario for the company’s financial stability and future growth.
This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.
FibroGen (FGEN) Analyst Forecast & Price Prediction
Start investing in FibroGen (FGEN)
Order type
Buy in
Order amount
Est. shares
0 shares